Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider Eric R. Olson sold 12,500 shares of the firm’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $21.85, for a total value of $273,125.00. Following the completion of the sale, the insider now directly owns 12,500 shares of the company’s stock, valued at approximately $273,125. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) traded up 1.73% during trading on Tuesday, hitting $24.16. The company’s stock had a trading volume of 11,842 shares. The company’s market capitalization is $632.51 million. The firm’s 50 day moving average is $18.30 and its 200-day moving average is $14.85. Syros Pharmaceuticals, Inc. has a 1-year low of $8.16 and a 1-year high of $24.35.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Monday, May 15th. The company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.10. The firm had revenue of $1.10 million during the quarter. Analysts forecast that Syros Pharmaceuticals, Inc. will post ($2.15) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Insider Sells $273,125.00 in Stock” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/08/08/insider-selling-syros-pharmaceuticals-inc-nasdaqsyrs-insider-sells-12500-shares-of-stock-updated.html.
Several analysts have commented on SYRS shares. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a report on Wednesday, April 12th. Wedbush reiterated an “outperform” rating and set a $22.00 target price on shares of Syros Pharmaceuticals in a report on Tuesday, May 16th. ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, Zacks Investment Research lowered Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Syros Pharmaceuticals has a consensus rating of “Buy” and an average target price of $20.67.
A number of hedge funds have recently bought and sold shares of SYRS. Wells Fargo & Company MN acquired a new stake in shares of Syros Pharmaceuticals during the first quarter worth $225,000. Bank of New York Mellon Corp acquired a new stake in shares of Syros Pharmaceuticals during the first quarter worth $185,000. Redmile Group LLC increased its stake in shares of Syros Pharmaceuticals by 0.5% in the first quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock worth $15,177,000 after buying an additional 4,300 shares during the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in shares of Syros Pharmaceuticals during the second quarter worth $343,000. Finally, Rhumbline Advisers purchased a new stake in shares of Syros Pharmaceuticals during the second quarter valued at approximately $198,000. Institutional investors and hedge funds own 49.45% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.